How to resolve discrepancies in MIOX2 detection across tissues or species?
Data contradiction analysis:
Tissue-specific expression: MIOX2 is abundant in kidneys but absent in heart/spleen . Validate using qPCR to confirm mRNA levels (e.g., 3000-fold higher MIOX2 vs. MIOX4 in Arabidopsis shoots) .
Cross-reactivity: Some antibodies (e.g., anti-MIOX4) may detect MIOX2 due to homology. Use gene-specific mutants (e.g., miox2-2 Arabidopsis) to confirm specificity .
How to design experiments linking MIOX2 activity to metabolic phenotypes?
Methodology:
Genetic models: Compare wild-type, miox2 mutants, and complemented lines (e.g., MIOX2:GFP) .
Metabolite profiling: Quantify myo-inositol and D-glucuronate via GC-MS in seedlings, leaves, and siliques .
Cell wall analysis: Measure UDP-D-glucuronate levels using HPLC in tissues with modulated MIOX2 expression .
Key finding: miox2 mutants show 2–5× elevated myo-inositol but no change in D-glucuronate in most tissues, suggesting compensatory pathways .
Why does MIOX2 antibody show non-specific bands in plant extracts?
How to distinguish MIOX2 from paralogs (e.g., MIOX4) in functional studies?